Revisiting China's response to coronavirus disease 2019.
10.1007/s11684-024-1059-5
- Author:
Guangbiao ZHOU
1
;
Saijuan CHEN
2
;
Zongjiu ZHANG
3
;
Zhu CHEN
4
Author Information
1. State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
2. State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine (Shanghai), Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. sjchen@stn.sh.cn.
3. Institute for Hospital Management, Tsinghua University, Beijing, 100084, China. zhangzongjiu@mail.tsinghua.edu.cn.
4. State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine (Shanghai), Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
- Publication Type:Editorial
- MeSH:
Humans;
COVID-19;
China/epidemiology*
- From:
Frontiers of Medicine
2023;17(6):1011-1013
- CountryChina
- Language:English